Is a mega merger the best option? (CNBC)

In light of the announcement of AstraZeneca’s preliminary approach to Gilead Sciences, John Rountree, was invited on CNBC to discuss the merits of the merger.

John discusses the merits of potential collaboration, highlighting existing collaborations in the industry, including AstraZeneca’s collaboration with The University of Oxford.

Considering the potential merger, John sides with analysts to question the merits of such a deal.

One of the big concerns of a mega merger is the potential impact on innovation, and John discusses some of the pitfalls R&D might face if the two companies do merge.

Discover our insight in R&D and how companies can achieve breakthrough innovation.